-
ALSO READ
Shilpa Medicare spurts after Telangana facility gets Health Canada GMP approval
Shilpa Medicare gains after Hyderabad facility gets EIR from USFDA
Shilpa Medicare launches breast cancer drug
Shilpa Medicare gains on launching breast cancer drug
Shilpa Medicare reports consolidated net loss of Rs 18.66 crore in the September 2022 quarter
-
Paves way for registration of products in UAE for commercialization
Shilpa Medicare's Bengaluru facility for manufacture and testing of Orodispersible films and Transdermal systems has been successfully registered with Ministry of Health, United Arab Emirates. This registration enables company to register the products (Orodispersible films and Transdermal systems) in UAE for commercialization.The facility is involved in manufacturing and testing of specialized dosage forms eg. Orodispersible Films and Transdermal systems. The facility is backed up with strong Research and Development of Orodispersible films and transdermal technologies. The GMP facility is equipped with state of art machinery for the needs of Global commercial requirements. The facility has already been issued GMP by UK MHRA.
The facility also manufactures dietary supplements in orodispersible films and was registered with US FDA Food Facility registry. The facility is actively exporting dietary supplements to US Market.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Subscribe to Business Standard Premium
Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!
Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.
Download the Business Standard App for latest Business News and Market News .
RECOMMENDED FOR YOU